Tissue Regenix Group PLC Tissue Regenix adds US patent

TIDMTRX

Tissue Regenix Group PLC

16 May 2014

Tissue Regenix Group plc

Tissue Regenix adds US patent related to 'tissue matrices for bladder implantation' to global exclusive licence portfolio

YORK, 16 May 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, has received the formal notice of allowance for a patent covering the use of its dCELL(R) technology in creating tissue implants for bladder repair.

The Group has exclusive access to a range of patents protecting its core process in major markets, and is adding to these by working with its technology partner, the University of Leeds, to protect individual products and processes.

Tissue Regenix's dCELL(R) decellularisation process removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold, which is not rejected by the patient's body, and which can then be used to repair diseased or worn-out body parts. This is the latest patent covering the use of the dCELL(R) decellularisation process and follows the recent announcement that a patent had been granted in China for meniscal implants to repair knee injuries.

Antony Odell, CEO of Tissue Regenix commented:"This latest patent adds to our fast-growing global portfolio, and will allow Tissue Regenix to use our dCELL(R) technology to help treat an array of urinary diseases and conditions in North America.

"Driven by an ageing population and increase in obesity, the urology device market is one of the largest markets of the medical devices industry, expected to be worth more than $2.5bn in the US by 2016.[1] Tissue Regenix has always planned for a global roll-out of dCELL(R) technology and shows our ambitious plans to address a wide-range of clinical needs."

Tissue Regenix has offices in the UK and US and is concentrated on the global commercialisation of its dCELL(R) technology.

ENDS

For Further Information

Tissue Regenix Group Plc: +44 19 0443 5176

Antony Odell

Ian Jefferson

Jefferies International Ltd: +44 20 7029 8000

Simon Hardy

Harry Nicholas

   Newgate Communications:                                                        +44 207 6806550

Andrew Adie

Andrew Jones

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL(R) technology platform.

[1] Millennium Research Group, 2012

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAFSKFLKLEFF

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024